What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the efficacy of its daily oral pill, orforglipron.
The study demonstrated that patients switching from injectable treatments like Zepbound to this oral alternative successfully maintained the vast majority of their weight loss. This development offers a promising solution to "needle fatigue," potentially allowing Lilly to capture patients looking for a convenient off-ramp from injectable therapies.
After the initial pop the shares cooled down to $1,062, up 1.9% from previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here.
What Is The Market Telling Us
Eli Lilly’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 3 days ago when the stock gained 3% on the news that the stock benefited as investors rotated capital out of the volatile technology sector and into defensive names.
As tech giants like Oracle and Broadcom faced scrutiny over rising costs and shrinking margins, Wall Street sought safer alternatives. Adding to the momentum, the company recently announced highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide. Investors viewed the successful trial as a strong validation of Lilly's deepening pipeline dominance in the massive and rapidly expanding cardiometabolic health market.
Eli Lilly is up 36.5% since the beginning of the year, and at $1,062 per share, it is trading close to its 52-week high of $1,110 from November 2025. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $6,195.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
